1. Search Result
Search Result
Results for "

LN

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

8

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149482
    LN5P45
    1 Publications Verification

    Cathepsin Cancer
    LN5P45 is an OTUB2 inhibitor (IC50: 2.3 μM). LN5P45 induces monoubiquitination of OTUB2 on lysine 31. LN5P45 can be used for research of tumor progression and metastasis .
    LN5P45
  • HY-18777
    KC7F2
    Maximum Cited Publications
    19 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Cancer
    KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC50 of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .
    KC7F2
  • HY-W278944

    Drug Derivative Cancer
    Antiproliferative agent-15 is an thienopyrimidine derivated anticancer agent. Antiproliferative agent-15 shows antiproliferative activity against human colon (HCT116 and HCT15) and brain (LN-229 and GBM-10) cancer cell lines .
    Antiproliferative agent-15
  • HY-169213

    KLF RAD51 Cancer
    LN-439A (compound LN-439A) is a BAP1 inhibitor that inhibits the growth of basal-like breast cancer by degrading KLF5. .
    LN-439A
  • HY-172541

    CXCR Cardiovascular Disease
    LN6023 (hydrochloride) (Compound 27) is a CXCR7 agonist. LN6023 (hydrochloride) induces the recruitment of β-arrestin in HEK293T cells expressing human CXCR7 (EC50 = 3.5 µM). LN6023 (hydrochloride) reduces the surface level of P-selectin in isolated and washed human platelets. LN6023 (hydrochloride) can be used to study platelet-mediated thrombosis .
    LN6023 hydrochloride
  • HY-162903

    Parasite Infection
    LN002 is an orally active anti-Cryptosporidium oxidase inhibitor for the study of cryptosporidiosis .
    LN002
  • HY-150794

    Others Cancer
    FLDP-8 is a curcuminoid analogues, has potent anti-cancer effects. FLDP-8 can induce cell death with an IC50 value of 4 μM in LN-18 cells .
    FLDP-8
  • HY-P6084

    NOD-like Receptor (NLR) p38 MAPK Apoptosis Inflammation/Immunology
    RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research .
    RP-220
  • HY-174732

    mRNA Inflammation/Immunology
    Human CSF3 mRNA encodes the human colony stimulating factor 3 (CSF3) protein, a member of the IL-6 superfamily of cytokines. CSF3 controls the production, differentiation, and function of granulocytes.
    Human CSF3 mRNA
  • HY-168721

    Microtubule/Tubulin Cancer
    Tubulin inhibitor 48 (compound 16) is an anti-cancer agent targeting tubulin. Tubulin inhibitor 48 has an IC50 of 0.1 and 0.07 μM for LN-229 and Capan-1 cell, respectively .
    Tubulin inhibitor 48
  • HY-149515

    Monoamine Oxidase Cancer
    MAO-IN-3 (Compound 5) is a reversible and competitive MAO inhibitor (Ki: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC50 of 0.8 μM. MAO-IN-3 can be used for cancer research .
    MAO-IN-3
  • HY-150791

    Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cancer
    FLDP-5 is a blood-brain barrier (BBB) penetrant curcuminoid analogues. FLDP-5 can induce production of ROS (Reactive Oxygen Species), DNA damage and cell cycle S phase arrest. FLDP-5 exhibits highly potent tumour-suppressive effects with anti-proliferative and anti-migratory activities on LN-18 cells .
    FLDP-5
  • HY-108637A

    MDM-2/p53 Cancer
    PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM , and a relative binding affinity (Kd) of 150 μM in Ln229 cells .
    PhiKan 083 hydrochloride
  • HY-12855A
    Lys05
    4 Publications Verification

    Lys01 trihydrochloride

    Autophagy Cancer
    Lys05 (Lys01 trihydrochloride) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
    Lys05
  • HY-18259

    HIF/HIF Prolyl-Hydroxylase Cancer
    103D5R (Compound 15) is an inhibitor for the activation of hypoxia-inducible factor-1 (HIF-1) with an IC50 of 35 µM, through reduction of the HIF-1α protein synthesis. 103D5R inhibits the proliferation of LN229 with IC50 of 26 µM .
    103D5R
  • HY-168437

    DNA/RNA Synthesis Cancer
    LIN28-IN-2 (Compound Ln268) blocks the binding of the zinc finger domain (ZKD) of Lin28 to RNA substrates, and inhibits Lin28a and Lin28b. LIN28-IN-2 inhibits the proliferation of Lin28-positive cancer cell and spheroid growth .
    LIN28-IN-2
  • HY-12855

    Autophagy Cancer
    Lys01, a dimeric form of Chloroquine (HY-17589A), is an autophagy inhibitor. Lys01 inhibits cell viability of 1205Lu, c8161, LN229, HT-29 cells with IC50s of 3.6, 3.8, 7.9, 6.0 μM. Lys01 can be used for anticancer research .
    Lys01
  • HY-155464

    VEGFR Aurora Kinase Cancer
    VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC50: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential .
    VEGFR-2/AURKA-IN-1
  • HY-403733B

    Androgen Receptor Prostaglandin Receptor Cancer
    (+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003) .
    (+)-JJ-450

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: